Cardiovascular

Acute coronary syndrome: post-MI arrhythmia management

Clinical Overview and When to Suspect Post-MI Arrhythmia

— <48 hours (early): Usually electrical instability from acute ischemia/reperfusion. Ventricular fibrillation (VF) and polymorphic VT in this window do not mandate ICD; they are considered transient.

— >48 hours (late): Often scar-mediated monomorphic VT or high-grade AV block from infarcted conduction tissue — these carry independent mortality risk and trigger device evaluation.

— Recurrent chest pain with new palpitations, syncope, or pre-syncope

— Sudden hemodynamic deterioration, hypotension, or pulmonary edema

— New bradycardia, escape rhythms, or wide-complex tachycardia on telemetry

— Cardiac arrest within 30 days of MI

— Inferior MI (RCA): Sinus bradycardia, AV nodal block (usually transient, responsive to atropine), increased vagal tone, RV infarct with bradyarrhythmia + hypotension

— Anterior MI (LAD): Infranodal block (Mobitz II, complete heart block with wide escape), bundle branch blocks, sustained VT/VF — worse prognosis, often needs pacing

— Tachyarrhythmias: VT, VF, AF, accelerated idioventricular rhythm (AIVR — reperfusion marker)

— Bradyarrhythmias: sinus brady, 1°/2°/3° AV block, new BBB

— Pump-related: AF from atrial stretch in heart failure

Post-MI arrhythmias are rhythm disturbances arising during or after acute coronary syndrome (ACS), reflecting ischemic injury, reperfusion, autonomic imbalance, scar-based reentry, or pump failure.

Timing framework drives etiology and prognosis:

Suspect arrhythmic complication in any post-MI patient with:

Anatomic correlations are exam-favored:

Mechanism categories:

Board pearl: AIVR (regular wide-complex rhythm 60–110 bpm) after fibrinolytics or PCI signals successful reperfusion — it is benign and should not be suppressed with antiarrhythmics. Treating it can precipitate asystole.

Step 3 management: Every post-MI patient gets continuous telemetry ≥24–48 h after revascularization; extend if arrhythmia, EF<40%, or hemodynamic instability is present.

Presentation Patterns and Key History

— Palpitations + chest pressure: Suggests recurrent ischemia driving ventricular ectopy or AF; consider stent thrombosis if within 30 days of PCI.

— Syncope or near-syncope: High-grade AV block, sustained VT, or pause-dependent torsades — always concerning, mandates admission and monitoring.

— Dyspnea + irregular pulse: New AF with rapid response, often from atrial ischemia or LV failure.

— Sudden collapse without prodrome: VF or pulseless VT — initiate ACLS.

— Exact timing relative to symptom onset and reperfusion (early vs late arrhythmia)

— Infarct location and culprit vessel (anterior vs inferior vs RV)

— Peak troponin and LVEF on index admission

— Current medications — particularly QT-prolonging agents (ondansetron, fluoroquinolones, azoles, methadone), beta-blocker dose, diuretics causing hypokalemia/hypomagnesemia

— Electrolyte trends — K+ <4.0 and Mg <2.0 promote ventricular arrhythmias post-MI

— Adherence to dual antiplatelet therapy (DAPT) — lapse raises stent thrombosis risk

— New ICD shocks

— Recurrent syncope

— Worsening orthopnea or PND (heart failure substrate for AF and VT)

Arrhythmia post-MI may present along a spectrum from asymptomatic telemetry findings to cardiac arrest. Anchor history to time since MI, infarct territory, and revascularization status.

Symptomatic clusters to recognize:

Critical historical elements to elicit:

Ambulatory red flags during follow-up calls or visits:

Key distinction: Sustained monomorphic VT >48 hours post-MI implies a fixed scar reentry circuit and carries ~2-fold mortality increase — fundamentally different from primary VF in the first 24 hours, which does not independently predict long-term mortality once the patient survives the acute event.

Step 3 management: When a post-MI patient calls reporting palpitations + lightheadedness, do not triage to outpatient Holter — send to ED for telemetry, ECG, troponin, and electrolytes. The pretest probability of dangerous arrhythmia is too high to manage remotely.

Physical Exam Findings and Hemodynamic Assessment

— SBP ≥90 mmHg with adequate perfusion

— Mentation intact

— No ongoing ischemic chest pain

— No acute pulmonary edema

— Adequate urine output

— Narrow-complex tachycardia + irregular: AF with RVR — auscultate for irregularly irregular rhythm, variable S1 intensity, pulse deficit

— Wide-complex regular tachycardia: Presume VT post-MI until proven otherwise (>90% probability in patients with structural heart disease)

— Bradycardia + cannon A waves: Suggests AV dissociation (complete heart block or VT)

— Hypotension + clear lungs + elevated JVP: Think RV infarct with bradyarrhythmia — preload-dependent, avoid nitrates and diuretics

— New S3 → LV failure substrate

— New systolic murmur post-MI → consider papillary muscle rupture (acute MR) or VSD — both can present with arrhythmia

— Pericardial friction rub → post-MI pericarditis (Dressler or early), may cause AF

— Cool extremities, mottling, narrow pulse pressure → cardiogenic shock

— Pulsus alternans → severe LV dysfunction

Physical exam in suspected post-MI arrhythmia must be rapid and protocolized — the goal is to determine stability so you can decide between electrical and pharmacologic management.

Hemodynamic stability criteria (all must be met):

Vital sign patterns:

Auscultation clues:

Peripheral signs:

CCS pearl: On the CCS case, when a post-MI patient becomes unstable with wide-complex tachycardia, your first orders are: "Place defibrillator pads," "Synchronized cardioversion 100 J" (or unsynchronized if pulseless/polymorphic), and "Continuous cardiac monitoring." Do not order amiodarone first in unstable VT — that loses points.

Board pearl: In inferior MI with bradycardia and hypotension, fluid bolus first before pressors or pacing — RV infarct physiology is exquisitely preload-dependent. A right-sided ECG (V4R ST elevation) confirms.

Diagnostic Workup — Initial Labs, ECG, and Biomarkers

— Compare to baseline post-MI ECG to identify new ST shifts (re-ischemia), QT prolongation, or conduction changes

— Document arrhythmia morphology: monomorphic VT (scar reentry) vs polymorphic VT (ongoing ischemia or long QT) vs torsades (pause-dependent, prolonged QT)

— Look for AV block level: 1° (PR >200 ms), Mobitz I (progressive PR lengthening, nodal), Mobitz II (fixed PR with dropped beats, infranodal), 3° (AV dissociation)

— Electrolytes: Maintain K+ ≥4.0 mEq/L and Mg ≥2.0 mg/dL post-MI — this is a guideline-supported target to suppress ventricular ectopy

— Repeat troponin if recurrent symptoms — rule out reinfarction or stent thrombosis

— BNP/NT-proBNP if HF suspected — drives AF substrate

— TSH (especially if AF) — hyperthyroidism precipitant

— CBC (anemia worsens demand ischemia), BUN/Cr (drug dosing)

— Drug levels if on digoxin; ABG if hypoxia or acidosis driving arrhythmia

— Bedside echocardiogram to assess LVEF, regional wall motion, RV function, mechanical complications (VSD, papillary rupture, free wall rupture, tamponade)

— Chest X-ray for pulmonary edema, ETT/lead position if intubated or paced

12-lead ECG is the cornerstone test — obtain immediately and repeat with any rhythm change.

Telemetry/continuous monitoring for all post-MI patients ≥24–48 h; longer if EF <40%, prior arrhythmia, or incomplete revascularization.

Targeted labs:

Imaging:

Board pearl: A new RBBB or LBBB with anterior MI is ominous — it signals extensive septal infarction with high risk of progression to complete heart block. Have transcutaneous pacing pads placed prophylactically even before symptomatic bradyarrhythmia develops.

Step 3 management: Order a right-sided ECG (V4R) whenever inferior MI is present with bradycardia or hypotension — confirming RV involvement changes management (give fluids, withhold nitrates and morphine).

Diagnostic Workup — Advanced and Confirmatory Studies

— LVEF is the single most important variable for ICD decision-making

— Identify ventricular aneurysm (substrate for monomorphic VT), thrombus, valvular complications

— Reassess EF at 40 days post-MI (or 90 days post-revascularization) — primary prevention ICD decisions hinge on this delayed measurement, because early stunning often improves

— Quantifies scar burden and gray zone (transition tissue) — emerging predictor of arrhythmic risk

— Identify atypical substrates (myocarditis mimicking MI, infiltrative disease)

— Indicated for syncope of unclear etiology post-MI with EF 36–40%

— Inducible sustained monomorphic VT supports ICD placement even if EF criteria not met

— Holter (24–48 h) for frequent symptoms

— Event monitor or implantable loop recorder (ILR) for infrequent syncope

— Mobile cardiac telemetry for higher-yield outpatient capture

— Indicated if recurrent ischemia is suspected as arrhythmia driver

— Polymorphic VT post-MI mandates re-evaluation of coronary anatomy and graft/stent patency

Once acute stabilization is achieved, advanced testing risk-stratifies for sudden cardiac death and clarifies arrhythmia substrate.

Transthoracic echocardiogram (formal, post-stabilization):

Cardiac MRI:

Electrophysiology study (EPS):

Ambulatory monitoring:

Coronary angiography (repeat):

Sleep study: OSA is a major reversible AF and nocturnal arrhythmia trigger — screen if symptoms suggest.

Key distinction: Primary prevention ICD requires LVEF ≤35% with NYHA II–III (or ≤30% NYHA I) measured at least 40 days after MI and ≥90 days after revascularization, on optimal GDMT. Secondary prevention ICD is indicated after sustained VT/VF >48 h post-MI not from reversible cause — no waiting period, no EF threshold required.

Board pearl: Don't place an ICD within 40 days of MI for primary prevention — the DINAMIT and IRIS trials showed no mortality benefit (arrhythmic deaths reduced but non-arrhythmic deaths increased). Bridge with wearable cardioverter-defibrillator (LifeVest) if very high risk.

Risk Stratification and First-Line Management Logic

— Unstable (hypotension, altered mental status, ischemic chest pain, pulmonary edema) → immediate electrical therapy

· Tachyarrhythmia → synchronized cardioversion (or defibrillation if VF/pulseless VT/polymorphic)

· Bradyarrhythmia → atropine 1 mg IV → transcutaneous pacing → transvenous pacing

— Stable → pharmacologic management with continuous monitoring

— VF/pulseless VT: ACLS — defibrillate 200 J biphasic, CPR, epinephrine 1 mg q3–5 min, amiodarone 300 mg bolus then 150 mg

— Stable monomorphic VT: IV amiodarone 150 mg over 10 min, then infusion; alternatively procainamide or sotalol

— Polymorphic VT with normal QT: Treat as ongoing ischemia — urgent angiography, beta-blocker, amiodarone

— Torsades (long QT): IV magnesium 2 g, correct K+, withdraw QT-prolonging drugs, overdrive pacing if recurrent

— AF with RVR: Rate control with beta-blocker (preferred post-MI) or diltiazem (avoid if EF<40% or acute HF); cardiovert if unstable

— Bradyarrhythmia/AV block: Atropine → pacing; permanent pacemaker if persistent >5–7 days or infranodal

— Early (<48 h) ventricular arrhythmias → treat acutely, no ICD indication

— Late (>48 h) → ICD evaluation per secondary prevention criteria

— GRACE score for overall ACS mortality

— LVEF, NYHA class, QRS duration for SCD risk

Management logic forks at three nodes: stability, rhythm category, and timing relative to MI.

Node 1 — Stability:

Node 2 — Rhythm category:

Node 3 — Timing:

Risk stratification tools:

CCS pearl: In a CCS case of stable monomorphic VT post-MI, your order set: "12-lead ECG," "IV access x2," "Defibrillator at bedside," "Amiodarone 150 mg IV bolus," "Continuous cardiac monitoring," "BMP, Mg, troponin," "Cardiology consult." Advance the clock and reassess. If becomes unstable → synchronized cardioversion at 100 J.

Pharmacotherapy — First-Line Drug Regimens

— Start within 24 h if no contraindications (acute HF, hypotension, bradycardia, high-degree AV block, active bronchospasm)

— Preferred agents: metoprolol succinate, carvedilol, bisoprolol (mortality benefit)

— Titrate to target HR 55–65 bpm; continue indefinitely

— Mechanism: blunt sympathetic drive, raise VF threshold, reduce reinfarction

— First-line for sustained VT, recurrent VF, and rhythm control of AF in HF post-MI

— Loading: 150 mg IV over 10 min, then 1 mg/min × 6 h, then 0.5 mg/min × 18 h

— Oral load: 400 mg TID × 1 week, then taper

— Monitor: LFTs, TFTs, PFTs, ophthalmology baseline; QT prolongation; drug interactions (warfarin, digoxin, statins)

— Second-line for ischemic VT/VF refractory to amiodarone, particularly during ongoing ischemia

— Not for prophylaxis — prophylactic lidocaine post-MI increases mortality (historical CAST-era lesson)

— First-line for torsades de pointes: 2 g IV bolus, repeat as needed

— Empiric repletion if Mg <2.0 mg/dL

— Rate control: beta-blocker first; amiodarone if HF

— Rhythm control: amiodarone preferred; avoid sotalol/dofetilide in early post-MI without EP guidance

— Anticoagulation: CHA₂DS₂-VASc–guided; triple therapy (DAPT + OAC) minimized to shortest duration per AUGUSTUS/PIONEER data — typically DOAC + P2Y12 inhibitor (clopidogrel) with brief aspirin

Beta-blockers are the cornerstone antiarrhythmic prophylaxis post-MI:

Amiodarone:

Lidocaine:

Magnesium sulfate:

Class IC agents (flecainide, propafenone): Contraindicated post-MI — CAST trial showed increased mortality due to proarrhythmia in structural heart disease.

Digoxin: May be used for AF rate control in HFrEF post-MI when beta-blockers insufficient; narrow therapeutic window; monitor levels.

For AF post-MI:

Board pearl: Never give class IC antiarrhythmics (flecainide, propafenone) or non-dihydropyridine CCBs as first-line rhythm/rate control in a patient with recent MI or reduced EF — both worsen mortality. Choose beta-blocker or amiodarone.

Procedures — Pacing, Cardioversion, Ablation, ICD

— Unstable VT (with pulse): synchronized, 100 J biphasic, escalate

— VF/pulseless VT/polymorphic VT: unsynchronized defibrillation 200 J biphasic

— AF: synchronized 120–200 J; sedate if conscious; anticoagulate if duration >48 h or unknown unless TEE-guided

— Transcutaneous pads — fastest, bridge only (painful, unreliable capture)

— Transvenous pacing indications post-MI:

· Symptomatic bradycardia unresponsive to atropine

· Mobitz II or complete heart block (especially with anterior MI)

· New bifascicular block + 1° AV block (trifascicular pattern)

· Alternating BBB

· Asystole

— Persistent (>5–7 days) high-grade AV block post-MI

— Symptomatic persistent sinus node dysfunction

— Anterior MI–related infranodal block often requires PPM even if intermittent

— Secondary prevention: Sustained VT/VF >48 h post-MI not from reversible ischemia — implant before discharge after optimization

— Primary prevention: EF ≤35% NYHA II–III (or ≤30% NYHA I) at ≥40 days post-MI and ≥90 days post-revascularization on GDMT, expected survival >1 year with good functional status

— Wearable cardioverter-defibrillator (WCD/LifeVest) bridges high-risk patients during the 40-day waiting period

— Indicated for recurrent monomorphic VT despite antiarrhythmics, especially with ICD shocks

— Substrate-based ablation of scar reentry circuits in post-infarct VT

— Also used for symptomatic AF refractory to medications

— Polymorphic VT or recurrent VF post-MI mandates repeat angiography — consider incomplete revascularization, stent thrombosis, or unaddressed culprit

Electrical cardioversion/defibrillation:

Temporary pacing:

Permanent pacemaker:

ICD placement:

Catheter ablation:

Revascularization revisited:

CCS pearl: When ordering an ICD on CCS, sequence is: optimize GDMT (beta-blocker, ACEi/ARB/ARNI, MRA, SGLT2i) → wait 40+ days → reassess EF → cardiology/EP consult → ICD placement. Skipping the waiting period or GDMT optimization loses management points.

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline prevalence of conduction disease, AF, and sinus node dysfunction

— Greater bleeding risk on anticoagulation — but withholding OAC for AF based on age alone is inappropriate; CHA₂DS₂-VASc already incorporates age

— Falls history does not automatically contraindicate anticoagulation — a patient must fall ~295 times/year for fall-related ICH risk to outweigh stroke prevention benefit

— Beta-blockers: start low (metoprolol succinate 12.5–25 mg daily), titrate slowly; monitor for orthostasis

— Amiodarone: enhanced toxicity risk (pulmonary, thyroid, neurologic) — use lowest effective dose

— ICD decision: weigh competing mortality, frailty, functional status, goals of care — shared decision-making essential

— Sotalol, dofetilide require renal dose adjustment with rigorous QTc monitoring

— Digoxin: reduce dose, follow levels (target 0.5–0.9 ng/mL in HF)

— Anticoagulation: apixaban preferred in CKD/ESRD; warfarin acceptable; avoid dabigatran if CrCl <30

— Electrolyte derangements (hyperkalemia, hypomagnesemia) are amplified arrhythmia substrates

— Amiodarone metabolized hepatically — monitor LFTs; reduce dose if elevated

— Warfarin dosing erratic — favor DOACs if liver function compensated, but avoid in Child-Pugh C

— Lidocaine clearance reduced — risk of CNS toxicity; lower infusion rates

— Review for QT-prolonging combinations (especially amiodarone + ondansetron + fluoroquinolone)

— Check for CYP3A4 interactions (amiodarone raises statin, digoxin, warfarin levels)

Elderly patients (>75 years):

Chronic kidney disease (CKD):

Hepatic impairment:

Polypharmacy considerations:

Board pearl: In an elderly patient with new AF post-MI and CHA₂DS₂-VASc ≥2, apixaban + clopidogrel (drop aspirin after 1–7 days) is the guideline-preferred regimen — minimizes bleeding while preserving stroke and stent protection (AUGUSTUS trial).

Step 3 management: Always recalculate creatinine clearance at each visit in elderly post-MI patients on DOACs — renal function fluctuates and dose adjustments are commonly missed in transitions of care.

Special Populations — Pregnancy, Young Patients, and Comorbid Subgroups

— Pregnancy-associated MI (often SCAD — spontaneous coronary artery dissection) carries elevated arrhythmia risk

— Safe antiarrhythmics: beta-blockers (metoprolol, labetalol — avoid atenolol due to IUGR), lidocaine, adenosine, procainamide

— Avoid: amiodarone (fetal thyroid, neurodevelopmental effects — use only if life-threatening), dronedarone (teratogenic)

— Anticoagulation: LMWH preferred; warfarin teratogenic in first trimester; DOACs not recommended

— Cardioversion is safe in pregnancy at all trimesters with fetal monitoring

— Investigate substance use (cocaine, methamphetamine), familial hypercholesterolemia, SCAD, vasculitis, hypercoagulable states

— Cocaine-induced MI: avoid beta-blockers in acute phase (unopposed alpha vasoconstriction risk); use benzodiazepines, CCBs, nitrates. Beta-blockers acceptable for chronic management after detox.

— Genetic arrhythmia syndromes (long QT, Brugada) may be unmasked by ischemic insult — family history critical

— Silent ischemia common — arrhythmia may be the presenting sign of recurrent infarct

— Autonomic neuropathy predisposes to fixed tachycardia and impaired bradycardic response

— Tight glycemic control reduces arrhythmia burden; SGLT2 inhibitors have mortality benefit in post-MI HFrEF

— Coexisting HFrEF amplifies arrhythmic risk — aggressive GDMT (ARNI, MRA, SGLT2i, beta-blocker) lowers SCD

— CRT-D indicated if EF ≤35%, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT

— Strongly associated with nocturnal AF, bradyarrhythmias, and refractory hypertension post-MI

— Screen with STOP-BANG; treat with CPAP

Pregnancy and peripartum:

Young patients (<45) post-MI:

Diabetes:

Heart failure overlap:

OSA:

Key distinction: Cocaine-associated chest pain and arrhythmia is the one ACS scenario where beta-blockers are contraindicated acutely — first-line is benzodiazepines for sympathetic surge, nitrates, and CCBs. Once detoxified and stable, standard post-MI beta-blocker therapy resumes.

Complications and Adverse Outcomes

— Leading cause of mortality in the first year post-MI

— Highest risk in first 30 days, particularly with EF ≤30%, unrevascularized disease, or recurrent ischemia

— Risk persists indefinitely with scar substrate

— May trigger ICD storm (≥3 appropriate shocks in 24 h) — medical emergency requiring sedation, IV beta-blockade, amiodarone, and consideration of ablation

— Proarrhythmia from antiarrhythmics themselves (especially class III: QT prolongation → torsades)

— Asystole, syncopal injuries, escape rhythm failure

— Hemodynamic collapse with RV infarct

— Thromboembolic stroke (5-fold baseline risk)

— Tachycardia-mediated cardiomyopathy if uncontrolled rate

— HF decompensation from loss of atrial kick

— Papillary muscle rupture, VSD, free wall rupture — typically days 3–7 post-MI

— New murmur + hemodynamic instability + arrhythmia → emergent echo

— Inappropriate shocks (AF with RVR, T-wave oversensing, lead fracture) — distressing, increase mortality

— Lead infection, endocarditis, pneumothorax during placement

— Battery depletion, generator failure

— Amiodarone: pulmonary fibrosis, thyroid dysfunction (both hypo and hyper), hepatotoxicity, corneal deposits, blue-gray skin, peripheral neuropathy

— Beta-blocker: bradycardia, fatigue, bronchospasm, masking hypoglycemia

— Anticoagulant: bleeding

Sudden cardiac death (SCD):

Recurrent VT/VF:

Bradyarrhythmia complications:

AF-related complications:

Mechanical complications presenting as arrhythmia:

ICD-related complications:

Drug-related complications:

Post-cardiac arrest syndrome: Anoxic brain injury, myocardial stunning, systemic inflammatory response — manage with targeted temperature management (32–36°C) for unconscious survivors of VF arrest.

Board pearl: A patient with an ICD who reports multiple shocks in rapid succession needs ED evaluation immediately. Interrogate the device, rule out ongoing ischemia, electrolyte derangement, and proarrhythmic drug exposure. ICD storm independently predicts mortality and warrants antiarrhythmic intensification ± urgent ablation.

When to Escalate — ICU, Consult, and Transfer Decisions

— Hemodynamic instability from any rhythm

— Sustained VT or VF, especially recurrent

— High-grade AV block requiring temporary pacing

— Post-arrest care, including TTM

— Mechanical complications (VSD, papillary rupture, tamponade)

— Need for vasopressors, inotropes, mechanical circulatory support (IABP, Impella, ECMO)

— Refractory ischemia with arrhythmia

— All ACS patients on admission

— New sustained arrhythmia

— Decisions about reperfusion strategy

— Recurrent VT, ICD candidacy, ICD storm, ablation consideration

— Symptomatic bradycardia for permanent pacing decisions

— Inherited arrhythmia syndrome suspicion

— Polymorphic VT or recurrent VF suggesting ongoing ischemia — repeat cath

— Mechanical complications for percutaneous or surgical intervention

— Mechanical complications, refractory ischemia with multivessel disease unsuitable for PCI, surgical ICD lead complications

— Community hospital without cath lab → urgent transfer for STEMI with arrhythmia

— Lack of EP services → transfer once stabilized for device implantation or ablation

— ECMO-capable center for refractory cardiogenic shock with arrhythmia

— 24 h arrhythmia-free on stable regimen

— Hemodynamic stability without vasoactive support

— Stable rhythm without need for continuous pacing

— Completed acute revascularization

ICU/CCU admission criteria post-MI with arrhythmia:

Cardiology consult — early:

Electrophysiology (EP) consult:

Interventional cardiology:

Cardiothoracic surgery:

Transfer considerations:

De-escalation criteria from CCU to floor:

CCS pearl: On CCS, the trigger to "move patient to CCU" should occur the moment you order vasopressors, transvenous pacing, IV amiodarone infusion, or post-arrest care. Delaying location change while ordering complex interventions on the floor loses management efficiency points.

Step 3 management: Document goals of care early — post-MI arrhythmia patients with multiple comorbidities may not desire ICD or aggressive escalation. Have the conversation before the next event, not during code.

Key Differentials — Same-Category (Arrhythmic) Causes

— Favor VT: AV dissociation, capture/fusion beats, QRS >140 ms, extreme axis deviation, concordance across precordial leads, history of structural heart disease

— In post-MI patients, wide-complex tachycardia is VT until proven otherwise (>90% probability)

— MAT: ≥3 distinct P-wave morphologies, often in COPD/hypoxia — treat underlying disease, avoid beta-blockers if bronchospastic

— AF: irregularly irregular, no discrete P waves

— AIVR: 60–110 bpm, often during reperfusion, benign — do not treat

— Slow VT: >110 bpm, treat as VT

— Junctional: narrow QRS, rate 40–60, no P waves or retrograde P; benign if hemodynamically stable

— CHB: AV dissociation, wider QRS if infranodal escape, often symptomatic

— Vagal: responsive to atropine, often transient with inferior MI

— SND: persistent, may require permanent pacing

— Torsades: long QT precipitant (drugs, electrolytes, congenital) — treat with Mg, correct cause, pace

— Polymorphic VT, normal QT: presume ischemia — beta-blocker, urgent angiography

Not every wide-complex or irregular rhythm in a post-MI patient is ischemia-driven. Differentials within the arrhythmia category:

Supraventricular tachycardia with aberrancy vs VT:

Atrial fibrillation with rapid ventricular response vs multifocal atrial tachycardia (MAT):

Accelerated idioventricular rhythm (AIVR) vs slow VT:

Junctional rhythm vs complete heart block:

Sinus bradycardia (vagal) vs sinus node dysfunction:

Torsades de pointes vs polymorphic VT with normal QT:

Brugada-pattern ECG unmasked by ischemia or fever — characteristic coved ST elevation V1–V2, may cause VF

Key distinction: AIVR is the only wide-complex rhythm post-MI you should celebrate rather than suppress — it confirms reperfusion. Treating it with amiodarone or lidocaine risks asystole because the ventricular focus may be the only pacemaker if sinus node is stunned.

Key Differentials — Other-Category Causes

— Hyperkalemia: Peaked T waves → widened QRS → sine wave → VF/asystole. Common in CKD + ACEi/ARB/MRA combinations. Treat with calcium gluconate, insulin/glucose, kayexalate or new K-binders, dialysis if severe.

— Hypokalemia/hypomagnesemia: U waves, prolonged QT, torsades risk

— Hypercalcemia: Shortened QT, bradyarrhythmias

— Acidosis/hypoxia: Lower VF threshold

— Digoxin toxicity: bidirectional VT, atrial tachycardia with block, junctional rhythms — treat with DigiFab

— QT-prolonging drugs: methadone, antipsychotics, fluoroquinolones, azoles, ondansetron, antidepressants

— Sympathomimetics: cocaine, methamphetamine, decongestants

— Caffeine, alcohol (holiday heart → AF)

— PE → sinus tachycardia, AF, RV strain pattern, occasionally VT

— COPD exacerbation → MAT, AF

— OSA → nocturnal bradyarrhythmias, AF

— Hyperthyroidism → AF, sinus tachycardia

— Pheochromocytoma → episodic tachyarrhythmias, hypertensive crisis

— Myocarditis can mimic post-MI presentation with arrhythmia + troponin elevation; cardiac MRI clarifies

— Sepsis → tachyarrhythmias, demand ischemia

— Lyme carditis → AV block (consider in endemic areas)

— Cardiac sarcoidosis, ARVC, HCM — may coexist with CAD, distinct substrate for VT

— Post-MI pericarditis or Dressler syndrome — AF, occasional VT; treat with high-dose aspirin or colchicine (avoid NSAIDs/steroids early post-MI as they impair healing)

Arrhythmias in a post-MI patient may originate from non-ischemic sources — missing these leads to mistreatment.

Electrolyte and metabolic derangements:

Drug-induced:

Pulmonary causes:

Endocrine:

Infectious/inflammatory:

Structural non-ischemic:

Pericardial:

Board pearl: Hyperkalemia mimics many post-MI rhythm changes — peaked T waves can be mistaken for hyperacute T waves of reinfarction. Always check a potassium before treating a wide-complex rhythm with antiarrhythmics; correcting K to >4.0 may resolve the rhythm without further intervention.

Secondary Prevention and Discharge Medications

— Aspirin 81 mg daily indefinitely

— P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel for ACS unless bleeding risk): 12 months default, may extend or shorten based on bleeding/ischemic balance

— High-intensity statin (atorvastatin 80 mg or rosuvastatin 40 mg); target LDL <70, ideally <55 in high-risk; add ezetimibe ± PCSK9 inhibitor if not at goal

— Beta-blocker indefinitely if EF reduced; ≥3 years if EF preserved

— ACEi/ARB if EF ≤40%, HTN, DM, or CKD; ARNI preferred over ACEi/ARB in HFrEF

— MRA (spironolactone, eplerenone) if EF ≤40% with symptomatic HF or DM

— SGLT2 inhibitor (empagliflozin, dapagliflozin) — mortality benefit in HFrEF and post-MI regardless of diabetes

— Continue amiodarone or other antiarrhythmics as indicated; reassess need at 3–6 months

— ICD interrogation schedule: 3 months post-implant, then every 6–12 months (often remote monitoring)

— Anticoagulation for AF: DOAC preferred; manage with P2Y12 for as short an aspirin overlap as tolerated

— Smoking cessation (varenicline, NRT, bupropion — bupropion lowers seizure threshold but is post-MI safe)

— Mediterranean diet, weight management, sodium restriction

— Cardiac rehabilitation referral — Class I recommendation, reduces mortality 20–25%

— Influenza, pneumococcal, COVID, RSV vaccinations

— Remote monitoring detects lead issues, arrhythmia recurrence, and battery status earlier than office visits

GDMT pillars post-MI — every patient gets evaluated for each class:

Arrhythmia-specific additions:

Lifestyle interventions:

Implantable device follow-up:

Step 3 management: At discharge after MI with arrhythmia, ensure the patient leaves with all GDMT classes addressed (each either prescribed or contraindication documented), a follow-up appointment within 1–2 weeks, cardiac rehab referral, and a documented medication reconciliation. Missing any one of these is a common Step 3 transitions-of-care pitfall.

Follow-Up, Monitoring, and Cardiac Rehabilitation

— Primary care or cardiology within 7–14 days to review medications, symptoms, adherence

— Cardiology at 4–6 weeks for clinical reassessment and EF re-evaluation

— At 40 days post-MI: repeat TTE to determine ICD candidacy (primary prevention)

— Then every 3–6 months in the first year, annually thereafter if stable

— Vitals each visit: HR (target 55–65 if on beta-blocker), BP (<130/80 generally), weight (HF surveillance)

— Labs at 4–12 weeks: lipid panel (titrate statin), BMP (renal function on ACEi/ARB/MRA, K+), HbA1c if diabetic

— Amiodarone monitoring: TSH and LFTs every 6 months; annual CXR and PFTs; ophthalmology if visual changes

— Anticoagulation: annual renal function; bleeding history at each visit

— Digoxin: level annually or with symptom change

— ICD/PPM interrogation per schedule; remote transmission alerts

— Educate patient: log shocks, syncope, palpitations

— Phase II: supervised exercise + risk factor modification, 36 sessions over 12 weeks

— Reduces all-cause mortality, cardiovascular mortality, recurrent MI, hospitalization

— Insurance covered (Medicare and most commercial) post-MI, post-PCI, post-CABG, HFrEF

— Recognize anginal equivalents, when to call 911 vs office

— Sexual activity: generally safe 1–2 weeks post-uncomplicated MI; avoid PDE5i with nitrates

— Driving restrictions: typically 1 week post-uncomplicated MI; after ICD for secondary prevention, no driving × 6 months; primary prevention, ~1 week (per AHA guidance, varies by state)

— Air travel: usually safe 2 weeks post-uncomplicated MI

Visit cadence post-discharge:

Monitoring parameters:

Device monitoring:

Cardiac rehabilitation:

Patient counseling:

Board pearl: A patient with an ICD placed for secondary prevention (post-VT/VF arrest) cannot drive a private vehicle for 6 months; commercial driving is permanently restricted. This is a frequently tested counseling pearl — document the discussion in the chart.

Ethical, Legal, and Patient Safety Considerations

— Discuss: device function, shock experience (described as "kick in the chest"), inappropriate shocks, infection risk, lead complications, battery replacements every 7–10 years

— Address end-of-life: ICDs can and should be deactivated when goals shift to comfort care to prevent shocks during dying — ethically and legally equivalent to withholding other life-sustaining therapies

— Document capacity assessment for elderly or cognitively impaired patients

— State-mandated reporting varies; physicians in some states must report patients with syncope or arrhythmia

— Commercial drivers (CDL): stricter post-MI and post-ICD restrictions per FMCSA

— 30-day post-discharge readmission rates highest for ACS + HF

— Mitigate with: medication reconciliation, teach-back education, scheduled follow-up, transitional care management billing codes

— Ensure DAPT prescription filled before discharge — premature discontinuation is the single strongest predictor of stent thrombosis

— Should occur during index admission, not only at decompensation

— Re-address after every major event (new arrhythmia, recurrent admission)

— Distinguish DNR/DNI from ICD deactivation — separate decisions

— Anticoagulation + DAPT bleeding events — minimize triple therapy duration

— QT-prolonging drug stewardship — pharmacy alerts, EHR clinical decision support

— Wearable defibrillator adherence — must be worn ≥22 h/day to be effective

— Cardiac arrest survivors may be referred for family screening (inherited arrhythmia syndromes)

— Workers' compensation if MI occurred in occupational context

— Women, Black, and Hispanic patients receive ICDs and guideline therapies at lower rates — actively counter implicit bias with checklist-driven discharge planning

Informed consent for ICD:

Driving regulations:

Transitions of care — high-risk window:

Code status conversations:

Patient safety:

Mandatory reporting / public health:

Disparities:

Step 3 management: When a hospice-bound patient with an ICD is enrolled, explicitly order ICD deactivation (cardiology or EP can do this with a programmer or magnet placement) — failure to do so subjects dying patients to repeated shocks and is a sentinel patient safety event.

High-Yield Associations and Rapid-Fire Facts

Inferior MI (RCA) → AV nodal block (responsive to atropine), often transient

Anterior MI (LAD) → infranodal block (Mobitz II, CHB with wide escape) — often needs pacing, worse prognosis

RV infarct triad: hypotension + clear lungs + elevated JVP — give fluids, avoid nitrates/morphine/diuretics

AIVR = reperfusion marker, do not treat

VF in first 24 h post-MI = no independent mortality penalty, no ICD

Sustained VT/VF >48 h post-MI = secondary prevention ICD before discharge

Primary prevention ICD = EF ≤35% NYHA II–III at ≥40 days post-MI, ≥90 days post-PCI/CABG

Wearable cardioverter-defibrillator bridges the 40-day waiting period

Class IC (flecainide, propafenone) = contraindicated in structural heart disease (CAST trial)

Lidocaine prophylaxis = harmful, increases mortality

Prophylactic magnesium = not routinely indicated; replete only if low

Torsades = IV magnesium, correct K+, stop QT-prolonging drugs, overdrive pace

Cocaine MI = avoid beta-blockers acutely; use benzodiazepines, CCBs, nitrates

Holiday heart = AF after alcohol binge; cardioversion + abstinence

Digoxin toxicity = bidirectional VT, atrial tach with block; treat with DigiFab

Post-MI pericarditis = treat with aspirin or colchicine, avoid NSAIDs/steroids (impair healing)

CHA₂DS₂-VASc ≥2 in men, ≥3 in women → anticoagulate

Triple therapy minimized: DOAC + clopidogrel, drop aspirin early (AUGUSTUS)

Beta-blocker target HR = 55–65 bpm

Statin target = LDL <70 (or <55 high-risk)

Cardiac rehab = Class I, 20–25% mortality reduction

ICD driving restriction = 6 months after secondary prevention, ~1 week after primary

Hospice + ICD = deactivate to prevent dying-process shocks

ICD storm = ≥3 shocks/24 h, requires ICU, sedation, IV beta-blockade, amiodarone, ± ablation

CRT-D = EF ≤35%, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT

SGLT2 inhibitors = mortality benefit in post-MI HFrEF independent of diabetes

Board pearl: The single highest-yield rule on post-MI arrhythmia questions: timing relative to MI determines ICD eligibility. Memorize the 48-hour cutoff for secondary prevention and the 40-day waiting period for primary prevention — at least one Step 3 question on this topic will hinge on these numbers.

Board Question Stem Patterns

Stem: 60M with anterior STEMI receives tenecteplase; 30 min later monitor shows regular wide-complex rhythm at 85 bpm, BP 120/80, asymptomatic. → Answer: observe (reperfusion AIVR). Avoid amiodarone/lidocaine traps.

Stem: 65M with anterior MI, EF 25%, NYHA II on optimal GDMT, 20 days post-PCI. → Answer: wait until ≥40 days post-MI, reassess EF; consider WCD bridge.

Stem: Patient 5 days post-MI with sustained monomorphic VT requiring cardioversion, EF 35%, fully revascularized. → Answer: ICD before discharge (no waiting period for secondary prevention).

Stem: 70F with inferior STEMI, HR 38, BP 88/50, lungs clear, elevated JVP. → Answer: IV fluids first (RV infarct), then atropine; avoid nitrates/morphine.

Stem: Post-MI patient on amiodarone and ondansetron develops polymorphic VT with long QT. → Answer: IV magnesium 2 g, stop offending drugs, correct K+.

Stem: Young patient with cocaine-induced ACS and tachyarrhythmia. → Answer: benzodiazepines, nitrates, CCBs; avoid beta-blockers acutely.

Stem: Patient with new AF, CHA₂DS₂-VASc 4, recent DES, on aspirin + ticagrelor. → Answer: switch to apixaban + clopidogrel (drop aspirin after 1 week); rate control with beta-blocker.

Stem: Anterior STEMI patient with new RBBB + LAFB + PR 220. → Answer: prophylactic transvenous pacing preparation; high risk of CHB.

Stem: Hospice patient with ICD receives multiple shocks. → Answer: deactivate ICD with programmer (or magnet temporarily).

Stem: Patient asks when he can drive after ICD for VF arrest. → Answer: 6 months of no driving for private vehicles; permanent restriction for commercial driving.

Pattern 1 — AIVR after thrombolytics:

Pattern 2 — Primary prevention ICD timing:

Pattern 3 — Secondary prevention ICD:

Pattern 4 — Inferior MI bradycardia:

Pattern 5 — Torsades:

Pattern 6 — Cocaine MI:

Pattern 7 — AF post-MI with stent:

Pattern 8 — Anterior MI with new bifascicular block:

Pattern 9 — ICD shocks at end of life:

Pattern 10 — Driving after ICD:

Board pearl: When the stem highlights timing, infarct territory, or a specific drug exposure, the answer almost always hinges on that detail — read these elements first before scanning answer choices.

One-Line Recap

High-yield recap bullets:

Post-MI arrhythmia management hinges on timing relative to infarct (early <48 h vs late >48 h), infarct territory (anterior LAD = infranodal block + scar VT vs inferior RCA = AV nodal block + RV-dependent bradyarrhythmia), and hemodynamic stability — with electrical therapy for instability, guideline-directed pharmacology (beta-blocker + amiodarone, avoiding class IC) for stable arrhythmias, and ICD decisions anchored to the 48-hour (secondary prevention, no waiting) and 40-day (primary prevention with EF ≤35%) cutoffs.

Timing is destiny: VF in first 24 h = no ICD; sustained VT/VF after 48 h = secondary prevention ICD before discharge; primary prevention ICD only after 40 days post-MI (or 90 days post-revascularization) with persistent EF ≤35%.

Territory predicts conduction disease: Anterior MI → infranodal block, often needs pacing; Inferior MI → AV nodal block, usually atropine-responsive; RV infarct → preload-dependent, fluids first, avoid nitrates/morphine.

AIVR is your friend — a wide regular rhythm 60–110 bpm post-reperfusion is benign and should never be suppressed; lidocaine or amiodarone risks asystole if the ventricular focus is the dominant pacemaker.

GDMT prevents arrhythmia recurrence: beta-blocker, ACEi/ARB/ARNI, MRA, SGLT2 inhibitor, statin, DAPT, and cardiac rehab together reduce SCD and reinfarction more than any single antiarrhythmic; class IC drugs are contraindicated, prophylactic lidocaine is harmful, and amiodarone is the workhorse when antiarrhythmic therapy is needed.

Step 3 management: Discharge checklist — medication reconciliation with all GDMT addressed, DAPT filled, follow-up within 7–14 days, cardiac rehab referral, 40-day EF reassessment scheduled, code status documented, driving restrictions counseled, and ICD deactivation plan in place for any patient transitioning to comfort care.